Business Wire

CA-CEPTON-TECHNOLOGIES

18.10.2019 00:02:05 CEST | Business Wire | Press release

Share
Laser System Partnership Sets Sights on Ending Toll Road Delays

A new technology partnership is set to transform road tolling for both providers and motorists alike by utilizing the latest advances in lidar technology and data analytics.

Cepton Technologies, Inc. has collaborated with industrial perception and machine learning experts, MechaSpin, to develop a lidar-based solution that produces detailed 3D classification of vehicles in real time for automated tolling applications. This next-generation solution combines Cepton’s Sora-P60 with MechaSpin’s MSx software to enable immediate profiling and classification of vehicles at highway speeds in a wide range of weather and lighting conditions.

Traditional tolling systems often depend on physical infrastructure to reduce vehicle speed, or tollbooths to allow for manual processing, which can cause congestion and frustration amongst motorists. Advanced systems that allow for faster tolling, however, are often subject to abuses such as leakage, while road-based sensors often fail due to wear and tear.

Cepton and MechaSpin’s solution addresses such challenges by eliminating the need for physical infrastructure while providing accurate data, such as vehicle velocity, size and axle count, in a format that can be integrated with other sensor, data capture and billing systems. At the same time, the hardware is designed for aerial installation and contains minimal moving parts, reducing the likelihood of failure.

Neil Huntingdon, Cepton’s VP of Business Development, said: “Our partnership with MechaSpin is founded on both businesses’ deep understanding of the unique and powerful capabilities of lidar, especially when it is teamed with problem solving software solutions.

“We believe that this partnership will bring major innovations to the tolling industry. Our Sora-P60 lidar delivers an unrivalled scan speed at 380Hz, making it possible to profile vehicles as they pass at highway speeds. Our partnership with MechaSpin will allow for faster, more accurate and lower cost management of our transport infrastructure as the number of vehicles continues to grow globally.”

Danny Kent, PhD, MechaSpin’s President, added: “The tolling industry lacks an integrated end-to-end solution for deploying 3D lidar for vehicle classification and tracking. MechaSpin and Cepton have partnered to deliver a solution for this need. Cepton's lidar technology coupled with MechaSpin's MSx Processing Engine offers a robust solution for tolling, intermodal and other transportation industry applications.”

Cepton will be showcasing its state-of-the-art lidar solutions at the 26th ITS World Congress in Singapore from October 21 to October 25, 2019. Please visit Cepton’s booth (B04) for more information or to arrange a live demo.

Founded in 2016 by Dr. Jun Pei and Dr. Mark McCord, Cepton is the only company in the industry to ship high-performance and low-cost lidar sensors directly to customers.

Lidar technology is not new, however its usage across industries is growing thanks to its power efficient, environmentally agnostic qualities. Like bats, which use sound waves during echolocation to measure distances and determine the location of an object, lidar utilises light waves from a laser to send a pulse of light and measure the amount of time it takes to reflect back from objects, making it possible to measure the distance between them. Since the speed of light is constant, distance can be easily calculated by measuring the time it takes for the beam to return.

Lidar systems use these pulses to create three-dimensional point clouds of their surrounding area, providing cars and other smart machines with highly accurate perception data to autonomously navigate.

Cepton's Micro Motion Technology (MMT™) is unique to the industry. Unlike traditional beam-steering technologies, such as spinning lidar and micro-electronical mechanical systems (MEMS), Cepton’s MMT architecture enables a mirrorless, frictionless and rotation-free system to increase the durability, reliability and manufacturability of the product, while delivering industry-leading range and resolution for highly accurate 3D sensing.

For more information about Cepton Technologies Inc., visit www.cepton.com

For more information about MechaSpin visit www.mechaspin.com

About Cepton Technologies, Inc.

Cepton Technologies, Inc. is a 3D sensing solutions provider shipping state-of-the-art lidar products for the automotive, security, transport infrastructure, industrial, IoT and mapping markets.

Founded in 2016 and led by industry veterans with deep experience in lidar and advanced imaging, Cepton is focused on the mass market commercialization of high performance, high quality lidar solutions for the automotive industry and beyond.

Cepton’s patented lidar technology delivers outstanding detection range and resolution, reliability and affordability, to enable perception for the fast-growing market for autonomous and smart machines.

For more information, visit: http://www.cepton.com/ .

Cepton is headquartered in San Jose, California, USA.

It also has offices in Germany, Canada and UK.

About MechaSpin

MechaSpin is an experienced Systems Integrator and Solution Provider dedicated to using lidar technology to make the world safer, more efficient and more productive. MechaSpin’s MSx Processing Engine provides advanced signal processing and machine learning algorithms for 3D lidar data.

Founded in 2010, MechaSpin is led by engineers that started their careers as participants in the DARPA Grand Challenges, fielding lidar technology for autonomous robotic vehicles. MechaSpin’s team is focused on bringing sensors, algorithms and technologies from the self-driving car industry into industrial markets such as material handling, tolling, port and terminal, intermodal, and more.

For more information, visit: http://www.mechaspin.com

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye